Accéder au contenu
Merck

Hypothalamic-pituitary-adrenal axis activity in older persons with and without a depressive disorder.

Psychoneuroendocrinology (2014-12-03)
D Rhebergen, N C M Korten, B W J H Penninx, M L Stek, R C van der Mast, R Oude Voshaar, H C Comijs
RÉSUMÉ

Altered functioning of the hypothalamic-pituitary-adrenal axis (HPA-axis) has been associated with depression, but findings have been inconsistent. Among older depressed persons, both hyperactivity and hypo-activity of the HPA-axis were demonstrated. However, most studies were population-based studies, with single cortisol measurements, lacking insight into diurnal patterns of HPA-axis functioning. We aim to provide insight into functioning of the HPA-axis, assessed by various salivary cortisol samples, in depressed older adults and non-depressed controls. Data were derived from the Netherlands Study of Depression in Older Persons. Cortisol levels of older persons without a lifetime diagnosis of depression and/or anxiety (n=109) were compared with older persons with a 6-month major depression diagnosis (n=311). ANCOVA analyses and random coefficient analysis on the four morning cortisol samples were performed. A possible U-shaped association between cortisol and depression status was examined. Depressed older persons showed higher morning cortisol levels at awakening (T1) and a less dynamic awakening response compared to non-depressed older persons. Dexamethasone suppression did not differ across groups. No U-shaped association between HPA-axis activity and depression was observed. We demonstrated a hypercortisolemic state and a diminished ability to respond to the stress of awakening among depressed older persons. Previously it was shown, that hypercortisolemic states may indicate a lifelong biological vulnerability for depression. Our findings expand on previous literature by demonstrating that in older persons the HPA-axis may become less responsive to stress, culminating in a further dysregulation of the diurnal cortisol-rhythm, superimposed on - possibly lifelong - hypercortisolemic states.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Dexaméthasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Hydrocortisone, BioReagent, suitable for cell culture
Sigma-Aldrich
Hydrocortisone, γ-irradiated, powder, BioXtra, suitable for cell culture
Sigma-Aldrich
Dexaméthasone, ≥98% (HPLC), powder
Sigma-Aldrich
Hydrocortisone, ≥98% (HPLC)
Sigma-Aldrich
Dexaméthasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexaméthasone, United States Pharmacopeia (USP) Reference Standard
USP
Hydrocortisone, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexaméthasone, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Hydrocortisone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hydrocortisone, meets USP testing specifications
Sigma-Aldrich
Dexaméthasone, meets USP testing specifications
Hydrocortisone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dexaméthasone, tested according to Ph. Eur.
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Hydrocortisone, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexaméthasone, VETRANAL®, analytical standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Hydrocortisone, British Pharmacopoeia (BP) Assay Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, British Pharmacopoeia (BP) Assay Standard